ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer(1,2). The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression(3), which makes ARID1A a poor therapeutic target. Therefore, it is of clinical...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Med
Autores principales: Shen, Jianfeng, Ju, Zhenlin, Zhao, Wei, Wang, Lulu, Peng, Yang, Ge, Zhongqi, Nagel, Zachary D., Zou, Jun, Wang, Chen, Kapoor, Prabodh, Ma, Xiangyi, Ma, Ding, Liang, Jiyong, Song, Shumei, Liu, Jinsong, Samson, Leona D., Ajani, Jaffer A., Li, Guo-Min, Liang, Han, Shen, Xuetong, Mills, Gordon B., Peng, Guang
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076433/
https://ncbi.nlm.nih.gov/pubmed/29736026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0012-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares